Oncology
ctDNA Is Becoming the New Argument Over Chemotherapy
New GALAXY data suggest ctDNA status may identify which patients with colorectal liver metastases benefit from adjuvant chemotherapy after surgery. The promise is precision. The danger is moving faster than the evidence.
The Money Is Moving Into Cancer Screening. The Evidence Still Has to Catch Up.
Europe Opens Another Lung Cancer Door to China-Origin Immunotherapy
In Australia, Cancer Medicine Delays Cost More Than Time
Cancer Progress Still Depends on Your Postcode
AI genomics market set to hit $9.3B by 2030, but regulation and equity gaps remain unresolved
Japan Approves MRD Testing. Price Will Decide Whether Patients Can Use It.
The Biomarker Test Cannot Wait Until Relapse
Cancer Treatment Is an Endurance Event. Stop Waiting for Patients to Lose Function.
When Brain Surgery Is Too Risky, Patients Still Need a Molecular Answer
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.